Adjunctive therapies in severe pneumonia in critical care patients

Infectious Disorders - Drug Targets

Volumn 11, Issue 4, 2011, Pages 395-400

  Tzovaras, N ^a   Karvouniaris, M ^a   Makris, D ^a   Zakynthinos, E ^a  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

Activated protein C; Corticosteroids; Pneumonia; Statins

Indexed keywords

CIPROFLOXACIN; DROTRECOGIN; GLUCOCORTICOID; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTINUOUS INFUSION; CORTICOSTEROID THERAPY; DRUG EFFICACY; HEMODYNAMICS; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE; MORTALITY; NONHUMAN; PNEUMONIA; SEPSIS; SEPTIC SHOCK; SEVERE PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 79961051098     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/187152611796504863     Document Type: Article

References (67)

1. ATS: Guidelines for the Management of Adults with Hospitalacquired, Ventilator-associated, and Healthcare-associated Pneumonia. Am. J. Respir. Crit. Care Med., 2005, 171(4), 388-416.
2. Ioanas, M.; Ferrer, M.; Cavalcanti, M.; Ferrer, R.; Ewig, S.; Filella, X., de la Bellacasa, JP.; Torres, A. Causes and predictors of nonresponse to treatment of ICU-acquired pneumonia. Crit. Care Med., 2004,32(4), 938-945.
3. Rhen, T.; Cidlowsky, J.A. Antiinflammatory action of glucocorticoids new mechanisms for old drugs. N. Engl. J. Med., 2005, 353(16), 1711-1723.
4. Annane, D.; Sebille, V.; Charpentier, C.; Bollaert, P.E.; François, B.; Korach, J.M.; Capellier, G.; Cohen, Y.; Azoulay, E.; Troché, G.; Chaumet-Riffaud P.; Bellissant, E. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA, 2002, 288(7), 862-871.
5. Sprung, C.L.; Annane, D.; Keh, D.; Moreno, R.; Singer, M.; Freivogel, K.; Weiss, Y.G.; Benbenishty, J.; Kalenka, A.; Forst, H.; Laterre, P.F.; Reinhart, K.; Cuthbertson, B.H.; Payen, D.; Briegel, J.; CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N. Engl. J. Med., 2008, 358(2), 111-124.
6. Meduri, G.U.; Golden, E.; Freire, A.X.; Taylor, E.; Zaman, M.; Carson, S.J.; Gibson, M.; Umberger, R. Methylprednisolone infusion in early acute severe ARDS: results of a randomized controlled trial. Chest, 2007, 131(4), 954-963.
7. Steinberg, K.P.; Hudson, L.D.; Goodman, R.B.; Hough, C.L.; Lanken, P.N.; Hyzy, R.; Thompson, B.T.; Ancukiewicz, M.; National heart, lung, and blood institute acute respiratory distress syndrome (ARDS) clinical trials network. Efficacy and safety of coricosteroids for persistent acute respiratory distress syndrome. N. Engl. J. Med., 2006, 354(16), 1671-1684.
8. Dellinger, R.P.; Levy, M.M.; Carlet, J.M.; Bion, J.; Parker, M.M.; Jaeschke, R.; Reinhart, K.; Angus, D.C.; Brun-Buisson, C.; Beale, R.; Calandra, T.; Dhainaut, J.F.; Gerlach, H.; Harvey, M.; Marini, J.J.; Marshall, J.; Ranieri, M.; Ramsay, G.; Sevransky, J.; Thompson, B.T.; Townsend, S.; Vender, J.S.; Zimmerman, J.L.; Vincent, J.L. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med., 2008, 34(1), 17-60.
9. Marik, P.E.; Pastores, S.; Annane, D.; Meduri, G.; Sprung, C.; Arit, W.; Keh, D.; Briegel, J.; Beishuizen, A.; Dimopoulou, I.; Tsagarakis, S.; Singer, M.; Chrousos, G.P.; Zaloga, G.; Bokhari, F.; Vogeser, M.; American College of Critical Care Medicine. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit. Care Med., 2008, 36(6), 1937-1949.
10. Tang, B.M.; Craig, J.C.; Eslik, G.D.; Seppelt, I.; McLean, A.S. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: A systematic review and meta-analysis. Crit. Care Med., 2009, 37(5), 1594-1603.
11. Barnes, P.J. Corticosteroid effects on cell signaling. Eur. Respir. J., 2006,27(2), 413-26.
12. Cooper, M.S.; Stewart, P.M. Corticosteroid insufficiency in Acutely ill Patients. N. Engl. J. Med., 2003, 348(8), 727-734.
13. Annane, D.; Maxime, V.; Ibrahim, F.; Alvarez, J.C.; Abe, E.; Boudou, P. Diagnosis of adrenal insufficiency in severe sepsis and septic shock. Am. J. Respir. Crit. Care Med., 2006, 174(12), 1319-1326.
14. Salluh, J.I.; Verdeal, J.C.; Mello, G.W.; Araújo, L.V.; Martins, G.A.; de Sousa Santino, M.; Soares, M. Cortisol levels in patients with severe community-acquired pneumonia. Intensive Care Med., 2006,32(4), 595-598.
15. Gotoh, S.; Nishimura, N.; Takahashi, O.; Shiratsuka, H.; Horinouchi, H.; Ono, H.; Uchiyama, N.; Chohnabayashi, N. Adrenal function in patients with community-acquired pneumonia. Eur. Respir. J., 2008, 31(6), 1268-1273.
16. Christ-Crain, M.; Stolz, D.; Jutla, S.; Couppis, O.; Müller, C.; Bingisser, R.; Schuetz, P.; Tamm, M.; Edwards, R.; Müller, B.; Grossman, A.B. Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. Am. J. Respir. Crit. Care Med., 2007, 176(9), 913-920.
17. Keh, D.; Boehnke, T.; Weber-Cartens, S.; Schulz, C.; Ahlers, O.; Bercker, S.; Volk, H.D.; Doecke, W.D.; Falke, K.J.; Gerlach, H. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock a double-blind, randomized, placebocontrolled, crossover study. Am. J. Respir. Crit. Care Med., 2003, 167(4), 512-520.
18. Sibila, O.; Luna, C.M.; Agusti, C.; Baquero, S.; Gando, S.; Patrón, J.R.; Morato, J.G.; Absi, R.; Bassi, N.; Torres, A. Effects of glucocorticoids in ventilated piglets with severe pneumonia. Eur. Respir. J., 2008, 32(4), 1037-1046.
19. Li, Y.; Cui, X.; Li, X.; Soomon, S.B.; Danner, R.L. Banks, S.M.; Fitz, Y.; Annane, D.; Natanson, C.; Eichacker, P.Q. Risk of death does not alter the efficacy of hydrocortisone therapy in a mouse E. Coli pneumonia model. Intensive Care Med., 2008, 34(3), 568-577.
20. Briel, M.; Boscacci, R.; Furrer, H.; Bucher, H.C. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection: a meta-analysis of randomized controlled trials. BMC Infect. Dis., 2005, 5: 101.
21. Confalonieri, M.; Urbino, R.; Potena, A.; Piattella, M.; Parigi, P.; Puccio, G.; Della Porta, R.; Giorgio, C.; Blasi, F.; Umberger, R.; Meduri, G.U. Hydrocortisone infusion in patients with severe community-acquired pneumonia: results of a randomized clinical trial. Am. J. Respir. Crit. Care Med., 2005, 171(3), 242-248.
22. Garcia-Vidal, C.; Calbo, E.; Pascual, V.; Ferrer, C.; Quintana, S.; Garau, J. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur. Respir. J., 2007, 30(5), 951-956.
23. Monton, C.; Ewig, S.; Torres, A.; El-Ebiary, M.; Filella, X.; Rañó, A.; Xaubet, A. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur. Respir. J., 1999, 14(1), 218-220.
24. Annane, D.; Meduri, G.U.; Marik, P.E. Critical illness related corticosteroid insufficiency and community-acquired pneumonia: back to the future. Eur. Respir. J., 2008, 31(6), 1150-1152.
25. Nawab, Q.; Golden, E.; Confalonieri, M.; Umberger, R.; Meduri, G. Glucocorticoid treatment in severe community-acquired pneumonia. Am. J. Respir. Crit. Care Med., 2007, 175, A594.
26. Siempos, I.I.; Vradakas, K.Z.; Kopterides, P.; Falagas, M.E. Adjunctive therapies for community acquired pneumonia: a systematic review. Journal of Antimicrobial Chemotherapy, 2008, 62(4), 661-668.
27. Salluh, J.I.F.; Póvoa, P.; Soares, M.; Castro-Faria-Neto, H.C.; Bozza, F.A.; Bozza, P.T. The role of corticosteroids in severe community acquired pneumonia: a systematic review. Crit. Care, 2008,12(3), R76.
28. Snidjers, D.; Daniels, J.; De Graff, C.S.; Van der Werf, T.S.; Boersma, W.G. Efficacy of corticoisteroids in community-acquired pneumonia: A randomised double-blinded clinical trial. Am. J. Respir. Crit. Care Med., 2010, 181(9), 975-982.
29. Marik, P.; Kraus, P.; Sribante, J.; Havlik, I.; Lipman, J.; Johnson, D.W. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia: a randomized controlled study. Chest, 1993,104(2), 389-392.
30. Mikami, K.; Suzuki, M.; Kitagawa, H.; Kawakami, M.; Hirota, N.; Yamaguchi, H.; Narumoto, O.; Kichikawa, Y.; Kawai, M.; Tashimo, H.; Arai, H.; Horiuchi, T.; Sakamoto, Y. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung, 2007, 185(5), 249-255.
31. Choi, G.; Hofstra, J.J.; Roelofs, J.J.; Florquin, S.; Bresser, P.; Levi, M.; van der Poll, T.; Schultz, M.J. Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats. Crit. Care Med., 2007, 35(5), 1362-1368.
32. Levi, M.; van der Poll, T. Recombinant human activated protein C: current insights into its mechanism of action. Crit. Care, 2007, 11(Suppl. 5), 3.
33. Yan, S.B.; Helterbrand, J.D.; Hartman, D.L.; Wright, T.J.; Bernard, G.R. Low levels of protein C are associated with poor outcome in severe sepsis. Chest, 2001, 120(3), 915-922.
34. Bernard, G.R.; Vincent, J.L.; Laterre, P.F.; LaRosa, S.P.; Dhainaut, J.F.; Lopez-Rodriguez, A.; Steingrub, J.S.; Garber, G.E.; Helterbrand, J.D.; Ely, E.W.; Fisher, C.J. Jr.; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med., 2001, 344(10), 699-709.
35. Bernard, G.R. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Crit. Care Med., 2003, 31(Suppl. 1), 85-93.
36. Laterre, P.F.; Garber, G.; Levy, H.; Wunderink, R.; Kinasewitz, G.T.; Sollet, J.P.; Maki, D.G.; Bates, B.; Yan, S.C.; Dhainaut, J.F.; PROWESS Clinical Evaluation Committee. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit. Care Med., 2005, 33(5), 952-961.
37. Mandell, L.A.; Wunderink, R.G.; Anzueto, A.; Bartlett, J.G.; Campbell, G.D.; Dean, N.C.; Dowell, S.F.; File, T.M. Jr.; Musher, D.M.; Niederman, M.S.; Torres, A.; Whitney, C.G.; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin, Infect, Dis., 2007, 44(Suppl. 2), 27-72.
38. Masterton, R.G.; Galloway, A.; French, G.; Street, M.; Armstrong, J.; Brown, E.; Cleverley, J.; Dilworth, P.; Fry, C.; Gascoigne, A.D.; Knox, A.; Nathwani, D.; Spencer, R.; Wilcox, M. Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy. J. Antimicrob. Chemother., 2008, 62(1), 5-34.
39. Vincent, J.L.; O'Brien, J.Jr.; Wheeler, A.; Wittebole, X.; Garg, R.; Trzaskoma, B.L.; Sundin, D.P. Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis. Crit. Care, 2006, 10(3), R74.
40. Vincent, J.L.; Bernard, G.R.; Beale, R.; Doig, C.; Putensen, C.; Dhainaut, J.F.; Artigas, A.; Fumagalli, R.; Macias, W.; Wright, T.; Wong, K.; Sundin, D.P.; Turlo, M.A.; Janes, J. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit. Care Med., 2005, 33(10), 2266-2277.
41. Kanji, S.; Perreault, M.M.; Chant, C.; Williamson, D.; Burry, L. Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study. Intensive Care Med., 2007, 33(3), 517-523.
42. Abraham, E.; Laterre, P.F.; Garg, R.; Levy, H.; Talwar, D.; Trzaskoma, B.L.; François, B.; Guy, J.S.; Brückmann, M.; ReaNeto, A.; Rossaint, R.; Perrotin, D.; Sablotzki, A.; Arkins, N.; Utterback, B.G.; Macias, W.L.; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotecogin alfa (activated) for adult patients with severe sepsis and a low risk of death. N. Engl. J. Med., 2005, 353(13), 1332-1341.
43. Sheffield, Mc. Multiple effects of statins in non-lipid disease states. US Pharm., 2004, 6, 38-54.
44. Terblanche, M.; Almog, Y.; Rosenson, R.S.; Smith, T.S.; Hackman, D.G. Statins and sepsis: Multiple modifications at multiple levels. Lancet Infect. Dis., 2007, 7(5), 358-368.
45. Majumdar, S.R.; McAlister, F.A.; Eurich, D.T.; Padwal, R.S.; Marrie, T.J. Statins, and outcomes in patients admitted to hospital and community acquired pneumonia: Population based prospective cohort study. BMJ, 2006, 333(7576), 999.
46. Stamatogiannis, N.; Makris, D.; Zakynthinos, E. Statins in Bacteremia, Sepsis and Pneumonia: Have We Found the Holy Grail? Recent Pat. Inflamm. Allergy Drug Discov., 2009, 10(3), 167-176.
47. Pruefer, D.; Scalia, R.; Lefer, A.M. Simvastatin inhibits leukocyte endothelial interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb. Vasc. Biol., 1999, 19(12), 2894-2900.
48. Weber, C.; Erl, W.; Weber, K.S.; Weber, P.C. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J. Am. Coll. Cardiol., 1997, 30(5), 1212-1217.
49. Yoshida, M.; Sawada, T.; Ishii, H.; Gerszten, R.E.; Rosenzweig, A.; Gimbrone, M.A. Jr.; Yasukochi, Y.; Numano, F. HMG-CoA reductase inhibitor modulates monocyte endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism. Arterioscler. Thromb. Vasc. Biol., 2001,21(7), 1165-1171.
50. Kallen, J.; Welzenbach, K.; Ramage, P.; Geyl, D.; Kriwacki, R.; Legge, G.; Cottens, S.; Weitz-Schmidt, G.; Hommel, U. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I domain. J. Mol. Biol., 1999, 292(1), 1-9.
51. WeitzSchmidt, G.; Welzenbach, K.; Brinkmann, V.; Kamata, T.; Kallen, J.; Bruns, C.; Cottens, S.; Takada, Y.; Hommel, U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med., 2001, 7(6), 687-692.
52. Wang, H.R.; Li, J.J.; Huang, C.X.; Jiang, H. Fluvastatin inhibits the expression of tumor necrosis factor -alpha and activation of nuclear factor-kappab in human endothelial cells stimulated by C-reactive protein. Clin. Chim. Acta, 2005, 353(1), 53-60.
53. Kothe, H.; Dalhoff, K.; Rupp, J.; Müller, A.; Kreuzer, J.; Maass, M.; Katus, H.A. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation, 2000, 101(15), 1760-1763.
54. Levi, M. Platelets. Crit. Care Med., 2005, 33(12), 523-525.
55. Steiner, S.; Speidl, W.S.; Pleiner, J.; Seidinger, D.; Zorn, G.; Kaun, C.; Wojta, J.; Huber, K.; Minar, E.; Wolzt, M.; Kopp, C.W. Simvastatin blunts endotoxin-induced tissue factor in vivo. Circulation, 2005,111(14), 1841-1846.
56. Grosser, N.; Hemmerle, A.; Berndt, G.; Erdmann, K.; Hinkelmann, U.; Schürger, S.; Wijayanti, N.; Immenschuh, S.; Schröder, H. The antioxidant defense protein heme oxygenase-1 is a novel target for statins in endothelial cells. Free Radic. Biol. Med., 2004, 37(12), 2064-2071.
57. Bourcier, T.; Libby, P. HMG-CoA reductase inhibitors reduces plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb. Vasc. Biol., 2000, 20(2), 556-562.
58. Lobo, S.M.; Lobo, F.R.; Bota, D.P.; Lopes-Ferreira, F.; Soliman, H.M.; Mélot, C.; Vincent. C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest 2003, 123(6), 2043-2049.
59. Mortensen, E.M.; Restrepo, M.I.; Anzueto, A.; Pugh, J. The effect of prior statin use on 30-day mortality for patients hospitalized with community acquired pneumonia (online exclusive article). Respir. Res., 2005, 6, 82.
60. Schlienger, R.G.; Fedson, D.S.; Jick, S.S.; Jick, H.; Meier, C.R. Statins and the Risk of Pneumonia: A population-based, nested case-control study. Pharmacotherapy, 2007, 27(3), 325-332.
61. Frost, F.J.; Petersen, H.; Tollestrup, K.; Skipper, B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest, 2007, 131(4), 1006-1012.
62. Martin, C.P.; Talbert, R.L.; Burgess, D.S.; Peters, J.L. Effectiveness of statins in reducing the rate of severe sepsis: A retrospective evaluation. Pharmacotherapy, 2007, 27(1), 20-26.
63. Almog, Y.; Shefer, A.; Novack, V.; Maimon, N.; Barski, L.; Eizinger, M.; Friger, M.; Zeller, L.; Danon, A. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation, 2004, 110(7), 880-885.
64. Kruger, P.; Fitzsimmons, K.; Cook, D.; Jones, M.; Nimmo, G. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med., 2006, 32(1), 75-79.
65. Liappis, A.P.; Kan, V.L.; Rochester, C.G.; Simon, G.L. The effect of statins on mortality in patients with bacteremia. Clin. Infect. Dis., 2001, 33(8), 1352-1357.
66. Hackman, D.G.; Mamdani, M.; Li, P.; Redelmeier, D.A. Statins and sepsis in patients with cardiovascular disease: A populationbased cohort analysis. Lancet, 2006, 367(9508), 413-418.
67. Schmidt, H.; Hennen, R.; Keller, A.; Russ, M.; Müller-Werdan, U.; Werdan, K.; Buerke, M. Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome. Intensive Care Med., 2006, 32(8), 1248-1251.